Innovative nucleic acid medicine targeted for prevention and treatment of malignant transformation of breast cancer
| Project/Area Number |
15K06885
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Ritsumeikan University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
木村 富紀 立命館大学, 薬学部, 教授 (40186325)
杉江 知治 関西医科大学, 医学部, 教授 (70335264)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2017: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 非コード性RNA / 乳癌 / 核酸医療 / 核酸医薬 |
|---|
| Outline of Final Research Achievements |
In this study, the following was clarified with respect to human EphA2 antisense RNA (AS). 1. Identification and expression of human EphA2 AS. 2. Design of sense deoxynucleotide (seODN) to inhibit human EphA2 AS expression and effects and interacting region on mRNA. 3. Physiological functions of breast cancer cells of human EphA2 AS. These results suggested that human EphA2 AS stabilizes the mRNA through the limited region and is involved in cell proliferation and cell migration. Furthermore, miRNAs targeting human EphA2 AS and mRNA were identified, and the possibility of a synergistic effect by combination with seODN was proposed.
|
Report
(4 results)
Research Products
(12 results)
